Chris Katz checks the drug, ARQ 501, under a light in one of the labs at ArQule in Woburn.
(JOANNE RATHE/GLOBE STAFF)
Despite losses, drug firm sees bright future
Trials pending on 3 products
Chris Katz checks the drug, ARQ 501, under a light in one of the labs at ArQule in Woburn.
(JOANNE RATHE/GLOBE STAFF)
WOBURN -- With several cancer drugs in the pipeline, executives of ArQule Inc. are optimistic about the future. (Full article: 840 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
